Literature DB >> 11588018

The contribution of interleukin (IL)-4 and IL-13 to the epithelial-mesenchymal trophic unit in asthma.

A Richter1, S M Puddicombe, J L Lordan, F Bucchieri, S J Wilson, R Djukanovic, G Dent, S T Holgate, D E Davies.   

Abstract

Interleukin (IL)-4 and IL-13 are key proinflammatory cytokines in asthma. Studies in transgenic mice show that both cytokines cause inflammation, but only IL-13 causes subepithelial fibrosis, a characteristic feature of asthma. We compared the in vitro profibrogenic effects of IL-4 and IL-13 using bronchial fibroblasts from asthmatic subjects. In the presence of transforming growth factor (TGF)-beta the cells transformed into contractile myofibroblasts and expressed alpha-smooth muscle actin and procollagen I. IL-4 and IL-13 also stimulated proliferation, but were relatively ineffective in promoting myofibroblast transformation. TGF-beta was more potent than the cytokines in stimulating release of endothelin-1 and vascular endothelial growth factor, whereas IL-4 and IL-13 were more potent stimuli for eotaxin release. Although neither IL-4 nor IL-13 induced profibrotic responses, both cytokines caused a corticosteroid-insensitive stimulation of TGF-beta2 release from primary bronchial epithelial cells. These data indicate that epithelial activation by IL-13 or IL-4 plays a critical role in initiating remodeling through release of TGF-beta2. TGF-beta2 then activates the underlying myofibroblasts to secrete matrix proteins and smooth muscle and vascular mitogens to propagate remodeling changes into the submucosa. In contrast, direct activation of submucosal fibroblasts by IL-4 and IL-13 has a proinflammatory effect via eotaxin release and recruitment of eosinophils into the airways.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11588018     DOI: 10.1165/ajrcmb.25.3.4437

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  71 in total

Review 1.  Airway smooth muscle and fibroblasts in the pathogenesis of asthma.

Authors:  Peter R A Johnson; Janette K Burgess
Journal:  Curr Allergy Asthma Rep       Date:  2004-03       Impact factor: 4.806

Review 2.  Role of interleukin-13 in asthma.

Authors:  Jonathan Corren
Journal:  Curr Allergy Asthma Rep       Date:  2013-10       Impact factor: 4.806

Review 3.  Interleukin-4, interleukin-13, signal transducer and activator of transcription factor 6, and allergic asthma.

Authors:  Douglas A Kuperman; Robert P Schleimer
Journal:  Curr Mol Med       Date:  2008-08       Impact factor: 2.222

Review 4.  The role of the epithelium in airway remodeling in asthma.

Authors:  Donna E Davies
Journal:  Proc Am Thorac Soc       Date:  2009-12

5.  Mechanical stimuli and IL-13 interact at integrin adhesion complexes to regulate expression of smooth muscle myosin heavy chain in airway smooth muscle tissue.

Authors:  Leena P Desai; Yidi Wu; Robert S Tepper; Susan J Gunst
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-06-03       Impact factor: 5.464

6.  Mitochondrial-targeted antioxidant therapy decreases transforming growth factor-β-mediated collagen production in a murine asthma model.

Authors:  Omar A Jaffer; A Brent Carter; Philip N Sanders; Megan E Dibbern; Christopher J Winters; Shubha Murthy; Alan J Ryan; Adam G Rokita; Anand M Prasad; Joseph Zabner; Joel N Kline; Isabella M Grumbach; Mark E Anderson
Journal:  Am J Respir Cell Mol Biol       Date:  2015-01       Impact factor: 6.914

Review 7.  Host responses in tissue repair and fibrosis.

Authors:  Jeremy S Duffield; Mark Lupher; Victor J Thannickal; Thomas A Wynn
Journal:  Annu Rev Pathol       Date:  2012-10-22       Impact factor: 23.472

Review 8.  Matrix remodeling in chronic lung diseases.

Authors:  Bon-Hee Gu; Matthew C Madison; David Corry; Farrah Kheradmand
Journal:  Matrix Biol       Date:  2018-03-17       Impact factor: 11.583

9.  Surfactant Protein-A Protects against IL-13-Induced Inflammation in Asthma.

Authors:  Dave Francisco; Ying Wang; Michelle Conway; Audriana N Hurbon; Alane B C Dy; Kenneth J Addison; Hong W Chu; Dennis R Voelker; Julie G Ledford; Monica Kraft
Journal:  J Immunol       Date:  2020-04-03       Impact factor: 5.422

Review 10.  Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials.

Authors:  Karen Au; Dinesh Khanna; Philip J Clements; Daniel E Furst; Donald P Tashkin
Journal:  Curr Rheumatol Rep       Date:  2009-04       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.